IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Wockhardt Poised for U.S. Drug Launch

1:20 PM MDT | July 31, 2007 | DR

Wockhardt (Mumbai), a pharmaceuticals and biotechnology company, has received tentative approval from the U.S. FDA to market terbinafine tablets in the U.S. Terbinafine is the generic version of Novartis’s branded drug Lamisil. The U.S. product patent for Lamisil expires on June 29. The U.S. market for terbinafine tablets, which are used to treat fungal infections, is estimated to be worth $680 million/year. “Our Wockhardt USA team is ready to embark on the launch of terbinafine the day the product patent expires,” says Habil Khorakiwala...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa